Novo Nordisk's Wegovy had been the only FDA-approved GLP-1 pill available since December 2025
Eight studies had low risk of bias (43, 5557, 61, 64, 71, 72), 11 studies had moderate risk of bias (44, 48, 50, 54, 58, 63, 65, 68, 74, 75, 79) and 22 studies had high risk of bias (16, 17, 23, 4547, 49, 5153, 59, 60, 62, 66, 67, 69, 70, 73, 7678, 80)
In fact, research published in Diabetes, Obesity, and Metabolism found that participants regained two-thirds of the weight they had previously lost after they stopped using Wegovy
Table of Contents What Are GLP-1 Medications and Why Do They Require Special Travel Care
Standard IGF-1 remains important for in vivo studies where IGFBP interactions are part of the biological system under investigation